COST-EFFECTIVENESS OF NT-PRO-BNP IN PATIENTS WITH CHRONIC HEART FAILURE WITH OR WITHOUT TYPE 2 DIABETES MELLITUS IN AUSTRIA

被引：0
|
作者：
Walter, E. [1 ]
机构：
[1] Inst Pharmaecon Res, Vienna, Austria
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA71
引用
收藏
页码：S47 / S47
页数：1
相关论文
共 50 条
  • [31] TELMISARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES MELLITUS TYPE 2
    Pavliukovych, N.
    Pavliukovych, O.
    Tryphonyuk, L.
    Kozar, M.
    ATHEROSCLEROSIS, 2019, 287 : E153 - E153
  • [32] The incidence of chronic heart failure in patients with type 2 diabetes mellitus
    Yeshniyazov, N. B.
    Medovchshikov, V. V.
    Tereshchenko, E. A.
    Khasanova, E. R.
    Kobalava, Z. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 253 - 253
  • [33] TELMISARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND DIABETES MELLITUS TYPE 2
    Pavliukovych, N.
    Pavliukovych, O.
    Kozar, M.
    ATHEROSCLEROSIS, 2022, 355 : E330 - E330
  • [34] Screening for type 2 diabetes mellitus: A cost-effectiveness analysis
    Hoerger, TJ
    Harris, R
    Hicks, KA
    Donahue, K
    Sorensen, S
    Engelgau, M
    ANNALS OF INTERNAL MEDICINE, 2004, 140 (09) : 689 - 699
  • [35] US Cost-Effectiveness of Saxagliptin in Type 2 Diabetes Mellitus
    Bergenheim, Klas
    Williams, Setareh A.
    Bergeson, Joette Gdovin
    Stern, Lee
    Sriprasert, Michelle
    AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (01) : 20 - 28
  • [36] Using NT pro BNP in patients with hypertension to prevent heart failure
    Dimitriu, I.
    Voiculescu, D.
    Sinescu, C.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2016, 46 : 15 - 16
  • [37] DRIVERS OF COST-EFFECTIVENESS IN TYPE-2 DIABETES MELLITUS
    McEwan, P.
    Foos, V
    Grant, D.
    Lamotte, M.
    Palmer, J. L.
    Lloyd, A.
    VALUE IN HEALTH, 2013, 16 (03) : A165 - A165
  • [38] Cost-effectiveness of candesartan in Germany for patients with chronic heart failure
    Voelkl, M
    Pirk, O
    Juenger, V
    VALUE IN HEALTH, 2005, 8 (06) : A96 - A96
  • [39] Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction among patients without type 2 diabetes
    Al-Badriyeh, Daoud
    Abushanab, Dina
    Chbib, Salma
    Kaddoura, Rasha
    Al Hail, Moza
    Rouf, Pallivalapilla Abdul
    El-Kassem, Wessam
    Shah, Jassim Zaheen
    Nair, Ramesh
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 396 - 397
  • [40] Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction
    Adrish, Muhammad
    Nannaka, Varalaxmi Bhavani
    Cano, Edison J.
    Bajantri, Bharat
    Diaz-Fuentes, Gilda
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 1183 - 1189
12345